PATIENT ALERT: Information regarding Coronavirus (COVID-19).  

Clinical Research & Trials

USO 19221

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Pa;clitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) (D9311C00001;GOG-3041; ENGOT-EN10)

 

Disease Types: GYN Cancer Research

Available at: